看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。/ p5 f: |9 S% m1 g- a
K) u+ K7 c }5 f
* d' N7 i+ ?/ E, dCurrently available feasibility data for possible combination strategies.
. M+ V0 A r! T5 x% W O: v————————————————————————————————
4 N- I- D/ ]: }! ]3 lCombination Feasibility according to preliminary data
* _2 `; S8 ?& G( a$ H+ v; T. v——————————————————————————————————
+ S3 c& N# r8 a5 h B& x6 T0 YBevacizumab + sorafenib Yes, reduced dose
% S5 L" _& S. H! \7 TBevacizumab + sunitinib† No 9 x% I# Z# O8 F) {. e! S3 _
Bevacizumab + temsirolimus Yes
4 P! b* D! D- j/ O: mBevacizumab + everolimus Yes 9 b, \; _8 T) p8 v5 B
Sorafenib + sunitinib ? 3 ~, G; Z* s% X1 Z* {
Sorafenib + temsirolimus Yes, reduced dose
; r1 o: m: v1 W+ H( u2 rSorafenib + everolimus Yes, reduced dose . i5 m8 Y u' Q0 z. y
Sunitinib + temsirolimus† No * I8 J7 X" Q* t3 x9 B
Sunitinib + everolimus ? $ A8 p- ]! [* }9 C+ B
Temsirolimus + everolimus ? & e! I! h3 k" L1 Q, D
————————————————————3 L4 W- i0 b; p
†Led to US FDA warning.1 A3 u, T* r' D" Y2 L
?: As yet unattempted combination.
( x, \) p% T R6 t. ]* U/ b' M |